Stereotactic ablative radiotherapy (SABR) offers patients with early-stage non-small cell lung cancer (NSCLC) an effective alternative to the standard of care surgery — with significantly fewer severe ...

Among 854 patients analyzed, durvalumab was initiated at a median of 5.6 weeks after CCRT (IQR, 4.0-8.3 weeks). When not considering the timing of durvalumab, patients who received durvalumab had ...

BERLIN October 17, 2025 – Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival ...

Efficacy profile of pembrolizumab for primary pulmonary NUT carcinoma: A systematic review and meta-analysis.

Incremental dose to neurogenic niches correlated with reduced overall survival: SVZ HR 1.306/Gy and hippocampus HR 1.222/Gy, indicating independent adverse prognostic impact.

A cohort study examines whether the use of common medications is associated with worse outcomes in patients with lung cancer ...

About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...

Lung cancer cells are able to take advantage of a person’s immune system, specifically T cells, to protect the tumor, ...

Small cell lung cancer (SCLC) is a fast-growing cancer that forms in the lung. It's one of two types of lung cancer. The other type is non-small cell lung cancer (NSCLC). SCLC is less common than ...